Live
FierceBiotechInnate ends work on NK cell engager in phase 1/2 trial as part of ongoing pipeline refocusFierceBiotechBiopharma funding dropped 20% in 2025 as companies doubled down on big bets: IQVIAEndpoints NewsOral peptides biotech Pinnacle Medicines gets $89M from US, China investorsRoche MediaPersonalising diabetes care: a holistic approach to cardiometabolic health - Roche10x Genomics News10x Genomics Stock Surges 21%, With A 5-Day Winning Spree - Trefis10x Genomics Blog10x Genomics Stock Surges 21%, With A 5-Day Winning Spree - Trefis10x Genomics Blog10x Genomics (NASDAQ:TXG) CEO Serge Saxonov Sells 10,000 Shares - MarketBeat10x Genomics News10x genomics CEO Saxonov sells $288,908 in stock - Investing.com10x Genomics Blog10x genomics CEO Saxonov sells $288,908 in stock - Investing.com10x Genomics Blog10x Genomics (NASDAQ: TXG) CEO sells 15,000 shares under Rule 10b5-1 plan - Stock Titan10x Genomics Blog10x Genomics Inc (TXG) Trading 4.54% Higher on Mar 25 - GuruFocusAgilentAgilent Technologies Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
FierceBiotech Mar 26, 2026

Innate ends work on NK cell engager in phase 1/2 trial as part of ongoing pipeline refocus

Innate ends work on NK cell engager in phase 1/2 trial as part of ongoing pipeline refocus

Original
Body unavailable. Use the original source.

Directory

59 All